MannKind (MNKD) CMO awarded 318,200 RSUs; Form 4 disclosure
MannKind (MNKD) filed a Form 4 showing its Chief Medical Officer acquired 318,200 shares of common stock via restricted stock units on 11/11/2025 at a price of $0.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MannKind (MNKD) filed a Form 4 showing its Chief Medical Officer acquired 318,200 shares of common stock via restricted stock units on 11/11/2025 at a price of $0. Following the grant, the reporting person beneficially owned 318,200 shares, held directly.
The RSUs carry a four-year vesting schedule: no shares vest on the first anniversary of the vesting determination date of September 29, 2025, and one-third vests on each anniversary thereafter until fully vested on the fourth anniversary.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock, $0.01 Par Value | 318,200 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
- F2. Four-year vesting schedule with no shares vesting on the first anniversary of the vesting determination date of September 29, 2025 and one-third on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did MannKind (MNKD) disclose in this Form 4?
What is the vesting schedule for the 318,200 MannKind RSUs?
Who is the reporting person and role at MNKD?
What was the transaction code for the MNKD RSU grant?
What does each RSU represent for MNKD?
AI-generated analysis. How Rhea-AI works. Not financial advice.